This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://linked.opendata.cz/resource/drugbank/drug/DB00365/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00365/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00365/identifier/bindingdb/
n18http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00365/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00365/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00365/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00365/identifier/drugbank/
n14http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://www.drugs.com/mtm/
n5http://linked.opendata.cz/resource/drugbank/patent/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00365/identifier/chemspider/
n22http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00365
rdf:type
n3:Drug
n3:description
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Grepafloxacin was withdrawn in the United States due to its side effect of lengthening the QT interval on the electrocardiogram, leading to cardiac events and sudden death. [Wikipedia]
n3:group
withdrawn
n3:halfLife
15 ± 3 hours
n3:indication
For treatment of adults with mild to moderate infections caused by susceptible strains of <i>Haemophilus influenzae</i>, <i>Streptococcus pneumoniae</i>, or <i>Moraxella catarrhalis</i>.
n3:manufacturer
n18:271B60A8-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00365 n14:DB00365
dcterms:title
Grepafloxacin
adms:identifier
n10:72474 n11:46507253 n12:C11368 n13:PA449812 n15:DB00365 n16:50117924 n17:65391 n19:Grepafloxacin
n3:mechanismOfAction
Grepafloxacin exerts its antibacterial activity by inhibiting bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, essential enzymes for duplication, transcription, and repair of bacterial DNA.
n3:packager
n18:271B60A7-363D-11E5-9242-09173F13E4C5
n3:patent
n5:5563138 n5:1340492
n3:toxicity
Withdrawn from the US market in 1999 due to associations with QTc prolongation and adverse cardiovascular events.
n3:foodInteraction
Drink liberally but avoid coffee. Take without regard to meals.
n3:proteinBinding
50%
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Grepafloxacin.htm
foaf:page
n21:grepafloxacin.html n22:grepa.htm
n3:IUPAC-Name
n4:271B60AD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B60B3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B60B2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B60AF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B60B0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B60B1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B60AB-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B60A9-363D-11E5-9242-09173F13E4C5 n4:271B60AC-363D-11E5-9242-09173F13E4C5 n4:271B60C3-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B60AA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B60B9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B60BA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B60B4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B60B5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B60B7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B60B6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B60B8-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly and extensively absorbed following oral administration. The absolute bioavailability is approximately 70%.
n3:affectedOrganism
Enteric bacteria and other eubacteria Streptococcus pneumoniae
n3:casRegistryNumber
119914-60-2
n3:category
n3:Bioavailability
n4:271B60BF-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B60C1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B60C2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B60BE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B60BD-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B60C0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B60AE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B60BB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B60BC-363D-11E5-9242-09173F13E4C5